Chris O'Neal 9/29/26 Chris O'Neal 9/29/26

Creative Cures

Twelve innovators share their solutions at the ACCJ’s Healthcare x Digital Pitch Day Event.

Startups convened once again in Osaka on February 13 for a chance to get Japan’s healthcare research to the people who need it through the American Chamber of Commerce in Japan (ACCJ) Healthcare x Digital (HxD) initiative. Now in its sixth year, the program spearheaded by the ACCJ Kansai chapter connects startups, academics, corporations, and government to develop ideas for community healthcare and individual patient care.

The 2026 HxD Pitch Event took place at Osaka’s Nakanoshima Qross and featured a panel discussion followed by two rounds of pitches from healthcare startups competing for five awards.

The event was cohosted by Nakanoshima Qross and supported by the US Commercial Service, part of the US Consulate General Osaka-Kobe. The top prize was a complimentary trip to the 2026 SelectUSA Investment Summit, a US Department of Commerce program that has generated more than $250 billion in new investment to date. This year’s summit ran May 3–6 in National Harbor, Maryland.

“The startups pitching today represent the best of Japan’s healthcare innovation,” Consul General Richard N. Larsen told the room at the opening of the event. “Your solutions address real challenges, and your willingness to compete on this stage demonstrates the entrepreneurial spirit driving progress in this sector.”

Hirokazu Shimoda, senior director at the Japan Agency for Medical Research and Development (AMED), previously worked at the Ministry of Economy, Trade and Industry and the Japan External Trade Organization’s San Francisco office. Leading the pre-event roundtable, he said that working groups are now operating across 17 fields to determine where Japan should concentrate its resources.

At the J.P. Morgan Healthcare Conference earlier this year, US investors kept asking him the same question: how AMED’s own subsidies could be used to coinvest in Japanese companies. He also pointed to Japan’s supporting industries—manufacturing, materials, robotics—as a real strength once paired with artificial intelligence (AI) and Japanese data, later noting that AMED’s funding is now extending to top-tier venture capital as well.

Japanese Healthcare: A Future Up for Debate

A panel discussion, moderated by Zimmer Biomet Director of Government Affairs Makoto Kawai, brought together Yasuhiko Iida, then of ACCJ President’s Circle member Eli Lilly Japan K.K., Dr. Okechi Oduori of Nakanoshima Qross, and Marisa Watanabe of the University of New South Wales, who joined remotely from Australia.

The conversation fell within HxD’s three standing focus areas: overcoming Japan’s urban–rural healthcare divide, reimagining the hospital of the future, and empowering patients to own their healthcare. As the discussion progressed, the topic turned to whether Japanese healthcare technology has to prove itself abroad before Japan’s own system will accept it.

Japan has strong basic research, Oduori said, but it isn’t as “gifted when it comes to social implementation,” which he described as getting high-quality research to the patients themselves.

Watanabe described a validation trap: Japanese corporate partners want proof of value before investing in technologies that first of all need investment to be tested.

“A lot of technologies worldwide are being lost because we just can’t get over that initial hurdle,” she said. One advantage, she noted, is already available: Australia’s approval process aligns closely with that of the US Food and Drug Administration (FDA), giving startups a faster on-ramp than the US process alone.

Japan’s acceptable margin of risk, Kawai argued, is effectively zero, which is why he told startups to prove themselves in other markets first.

Watanabe raised a second fix of her own for lower-risk categories. “[We need] a sandbox system where we can actually try to speed up approval processes for certain types of technologies that are less [of a] health risk,” she said, as an example pointing to fall-prevention technology that could be validated safely, given available countermeasures if something goes wrong, and processed faster as a result.

Oduori differed slightly, arguing that startups should work with regulators from day one. “There is always an opportunity that we can work closely with the regulatory authorities at the very beginning, incorporating them as you do your studies,” he said.

Kawai added: “It’s just easier for people to go outside, prove it, and come back with that proof. To get Japanese to jump off the boat, you tell them that everybody already has jumped off.”

The conversation ranged further, with L.E.K. Consulting Partner Christian Boettcher raising the long-standing tension between Japan’s Ministry of Health, Labour and Welfare and the Ministry of Economy, Trade and Industry over how fast to move on approvals. Eli Lilly Japan’s Iida argued that patients increasingly want quality of life rather than a fix for a disease, pointing to Asics as an example of a wellness-adjacent company with few avenues for talking to doctors or pharmaceutical companies.

A question from the floor turned to whether Japanese universities still favor publishing research over patenting it. Oduori said the situation has improved, with more universities now advising on intellectual property, but that patents held inside university walls still complicate industry collaboration.

By the end of the discussion, when an audience member asked who should actually guide a startup from concept to market, Oduori said that getting a startup to commercialization takes the same kind of cooperation that your fingers require when you eat with chopsticks.

“Know who is more important than know-how,” Kawai said, closing the panel.

ACCJ–Kansai Governor Kevin Yamaga-Karns, associate vice president of legal affairs at Eli Lilly Japan, then presented the panelists with certificates of appreciation.

Let the Games Begin

The pitch competition’s 12 healthcare startups presented their solutions to an expert panel of judges: Mari Ogihara of AstraZeneca K.K., Yasuhiko Iida of Eli Lilly Japan, Dr. Robert Brand of EY, Dr. Yu Moriguchi of Osaka University and Nakanoshima Qross, Akira Omae of The Kobe Shimbun and Anchor Kobe, and L.E.K. Consulting’s Boettcher. Competing this year were:

SalivaTech Co., Ltd.
Nonat Inc.
I.W.G. Inc.
PurinoScience
Craif, Inc.
MIG Inc.
Heliex Inc.
Quadlytics Inc.
Ekei Labs
Aman Wellness Solutions (AWS LLC)
VisionPath
Xupra

SalivaTech’s SalivaChecker, an AI-powered saliva test that screens for six cancers from a single sample, already serves more than 110,000 users. Chief Executive Officer Dr. Makoto Sunamura, a pancreatic surgeon at Tohoku University Hospital, framed the product as screening rather than diagnosis, with the company’s US launch built around CLIA-certified labs ahead of full FDA approval.

According to World Health Organization data cited by Nonat Inc., just 18 percent of high-risk pregnant women worldwide receive proper treatment. With that in mind, the company pitched a wearable device and an AI system for remote pregnancy monitoring.

I.W.G. Inc., founded by a team that previously scaled a medical AI startup to unicorn status—meaning a valuation of more than $1 billion—pitched two products: AI Referral, which standardizes referral and discharge data across formats, and DOCloud, a workflow and communications platform that the company said has already cut client data transfer time from four days to 40 seconds, alongside a 90 percent drop in human error. I.W.G. said it has been selected by the Mayo Clinic as the first and only Japanese company in that ecosystem.

No approved drug exists anywhere for sarcopenia, the natural loss of muscle tissue due to age, according to PurinoScience Chief Executive Officer Kotaro Hisamoto. He pitched an oral combination therapy built on a repurposed gout medication that Japanese research already links to lower sarcopenia rates combined with a marketed adenosine triphosphate, or ATP. According to cofounder Ken Okamoto, of the University of Tokyo, the precursor restores muscle energy through the body’s own purine salvage pathway.

Craif, Inc. brought a related pitch built on an already-proven distribution network: its urine-microRNA platform serves more than 50,000 users through some 2,000 clinics and 4,000 pharmacies, and its new product, miSignal Age, estimates biological age and cardiometabolic risk from the same single sample.

Half the people in their forties and fifties, MIG Inc. President and Chief Executive Officer Hidetaka Kai told judges, already show the first brain-cell changes of Alzheimer’s disease, with no symptoms at all. The startup’s solution to this is a six- to eight-minute virtual reality test. The results, Kai said, correlate closely with p-tau181, a blood biomarker for the disease. New Alzheimer’s drugs from companies such as Eisai, Biogen, and Eli Lilly exist, but patients often arrive at the hospital too late to use them, he said.

Heliex Inc., based in Akita Prefecture, pitched “health intelligence” based on CT scans for personal trainers and nutritionists.

Quadlytics Inc. built its pitch around the fact that an epilepsy diagnosis in Japan often means immediate loss of a driver’s license. The company’s development, the Epilepsy Alarm, is a wearable that reads heart-rate variability to predict a seizure one to 20 minutes before it occurs. The company cited more than $10 billion in annual US emergency costs tied to epilepsy hospitalizations.

Ekei Labs, based at the Okinawa Institute of Science and Technology, pitched epigenetics chemistry paired with AI to predict drug trial success before a trial runs, claiming a 30 percent cut in trial costs, a 50 percent cut in trial failures, and 55 times more data per dollar spent than conventional methods.

Aman Wellness Solutions pitched a cross-border second-opinion platform connecting Japanese and US medical care. Founder Sahiora Nurujai was candid about a barrier few others mentioned, saying many Japanese hospitals are running deficits and so remain reluctant to devote domestic resources to foreign patients.

VisionPath Chief Executive Officer Jake Smith, a first-year student at Ritsumeikan University, pitched a smart walker inspired by his grandmother’s difficulty crossing a room for a glass of water. The company has not yet incorporated, but it has already secured a spring clinical trial with the city of Minoh.

Xupra closed the pitches with a foundational AI model built for pharmaceutical data, pitched through the story of a fictional drug rep, Yamada-san, coached before doctor visits and corrected after them. The company said it already runs a paid pilot with more than 400 users at a major pharmaceutical company.

And the Winners Are …

After deliberation, the judges announced five awards:

SelectUSA Investment Summit Award: SalivaTech Co., Ltd.
Anchor Kobe Award (Kobe City): Aman Wellness Solutions
Nakanoshima Qross Award: PurinoScience
Osaka Bio Headquarters Award (Osaka Prefecture): Quadlytics Inc.
Osaka LifeScience Nexus Award: VisionPath

SalivaTech’s win secured its trip to the SelectUSA Investment Summit, following the path of past HxD winners such as Anaut Inc. and AMI Inc., both of which used their trips to Maryland to build connections with US investors and partners.

An Ongoing Effort

“This is not the last event,” Boettcher told the startups after announcing the results. “We had companies in the past that reapplied and then won. So, thank you for everybody’s efforts today, and congratulations to the winners.”

The next HxD event—Connected by Data, Powered by AI, Enabled by Technology: Reimagining People-Centered Care—is scheduled for October 30 at Nakanoshima Qross.

John Amari 12/17/24 John Amari 12/17/24

Transforming Treatment

The annual HxD Pitch Day brought together five innovative start-ups that are bringing healthcare innovation to a changing world.

ACCJ Healthcare x Digital Pitch Day again shines the spotlight on innovation

Osaka’s Nakanoshima Qross, a new international hub for healthcare innovation, welcomed the American Chamber of Commerce in Japan (ACCJ) on November 1 as host of the annual Healthcare x Digital (HxD) Pitch Day.

Led by the ACCJ Kansai Chapter and the Healthcare Committee, the HxD platform brings together innovators from multidisciplinary backgrounds to collaborate and develop ideas alongside some of the world’s leading healthcare and pharmaceutical companies.

Simone Thomsen, president and representative director of Eli Lilly Japan K.K. and an ACCJ governor, kicked off the event by addressing healthcare challenges amplified by Japan’s aging population and rising costs.

Digitalization, she noted, is key to overcoming barriers in healthcare. She emphasized the Kansai region’s burgeoning ecosystem of start-ups and the importance of fostering partnerships for sustainable solutions—something at the heart of this year’s theme, Transforming Healthcare: Collaborating in a Changing World.

“Led by the ACCJ Kansai Chapter and the Healthcare Committee, the HxD platform brings together innovators from multidisciplinary backgrounds to collaborate and develop ideas alongside some of the world’s leading healthcare and pharmaceutical companies.”

Following Thomsen’s remarks, Dr. Yoshiki Sawa, chairman of the Organization for Advanced Healthcare Innovation at Nakanoshima Qross, delivered the keynote address.

A renowned cardiac surgeon and innovator, Sawa shared insights into cutting-edge research at Nakanoshima Qross, including the development of iPS cell-derived cardiac patches for regenerative medicine. He highlighted the unique collaboration opportunities provided by the center, where research, development, and medical applications coexist under one roof.

A roundtable discussion followed with panelists Kunihiro Ohyama of Microsoft Japan, Dr. Junji Fukumori of Osaka Keisatsu Hospital, Taro Tanaka from Osaka Prefecture, and Koji Deguchi from Kobe City. Topics included the role of public–private partnerships in fostering innovation, the importance of global collaboration, and strategies for addressing healthcare inequities.

Tanaka, the director of Osaka’s Smart City Strategy Division, shared how the city is leveraging digital health initiatives, while Ohyama, Microsoft Japan’s healthcare industry lead, discussed the transformative potential of artificial intelligence (AI) and the Internet of Things in healthcare, among other themes that were raised.

Game Changers

The heart of HxD Pitch Day was the competition in which five innovative start-ups presented their solutions to transform healthcare. Competing this year were:

Bipsee Inc.
Elcyo Co., Ltd.
ImmuniT Research, Inc.
Pittan Inc.
Seven Point One Inc.

Judging were industry experts, including EY Strategy & Consulting’s Christian Boettcher, Eli Lilly Japan’s Yasuhiko Iida and Miyu Harada, Innovation Dojo Japan’s Joshua Flannery, and AstraZeneca’s Torsten Kanisch and Mari Ogihara, who is also the community manager for the i2.JP open innovation initiative. Their expertise provided valuable feedback to the start-ups. Bipsee, Pittan, and Seven Point One received honors.

Bipsee, winner of the HxD Award, impressed judges with its mental health therapy based on virtual reality (VR). Chief Operating Officer Kohei Kamikihara explained how VR could alleviate the burden of cognitive behavioral therapy on clinicians and patients by offering an immersive, self-guided alternative. The company’s eight-week program helps patients intuitively learn coping mechanisms for depression, thereby reducing relapse rates, Kamikihara said.

Elcyo Co., Ltd. presented its groundbreaking Elcyo Lens, an autofocus glasses system integrating liquid crystal lens technology and AI. The glasses dynamically adjust prescriptions in real-time, reducing eye strain caused by digital devices. Chief Executive Officer Sunri Lee noted that the glasses are not just tools for vision correction but guardians of eye health. Set to launch in 2025, the product aims to transform vision care.

ImmuniT Research, Inc. unveiled its advanced immune system quantification technology, focusing on its Th7R cell marker, which aids in cancer immunotherapy. By providing precise data for personalized treatment, ImmuniT is redefining how clinicians approach immune-related diseases. The company has a vision to revolutionize cancer treatment and realize a society of longevity, said Chief Scientific Officer Akio Ametani.

Recipient of the Microsoft Award, Seven Point One Inc. pitched AlzWIN, their AI-powered dementia screening solution that utilizes verbal fluency. The solution looks to empower individuals through early dementia diagnosis and management.

SelectUSA

The SelectUSA Award went to Pittan Inc., which showcased Nutrifull, a system that analyzes sweat composition to visualize health and nutritional status. Designed to enable more people to accurately monitor their health status on a regular basis, Nutrifull aims to extend life expectancy by preventing lifestyle-related diseases.

HxD’s connection to the SelectUSA Investment Summit, a US government program designed to attract and support international business investments in the United States, is a standout aspect of the competition. The tie-up is supported by the Commercial Service office in Japan and began last spring, when US Ambassador to Japan Rahm Emanuel attended Pitch Day on April 17 and saw Anaut Inc. punch its ticket to June’s SelectUSA Summit in National Harbor, Maryland. The company won for its clinical AI software that enables precision mapping of the human body during surgery.

With its win this year, Pittan Inc. secured the opportunity to win a trip to Maryland for the next summit, to be held from May 11 to 14, where it will gain exposure to US investors and partners. The SelectUSA collaboration underscores the ACCJ’s commitment to fostering global opportunities for Japanese start-ups.

Building Bridges

Kanisch from AstraZeneca remarked on the ingenuity of the start-ups, highlighting the potential for Japan to lead in digital health innovation. He also shared his excitement at seeing ambitious ideas taking shape through HxD.

Following the awards ceremony, the event closed with a networking session, offering participants the chance to forge partnerships that could shape the future of healthcare in Japan—and globally.

HxD Pitch Day demonstrated the power of collaboration in addressing healthcare challenges. By bringing together diverse stakeholders, the event not only showcased Japan’s potential as a global healthcare innovation hub but also fostered connections with international markets.

As Thomsen from Eli Lilly Japan concluded in her opening remarks: “This world is changing. We have a true VUCA [volatility, uncertainty, complexity, and ambiguity] world where there is a lot of instability.”

And while noting societal challenges such as the increase in aging populations, which is impacting healthcare systems, especially in Japan, she also highlighted the opportunities.

“Digitalization and technology will help us to accelerate [innovative solutions] further,” she said. “This is why, today, we wanted to come together, and what better venue could we think of than the new Nakanoshima Qross, which really is an international hub for healthcare innovation.”

C Bryan Jones 9/15/21 C Bryan Jones 9/15/21

HxD 2021

Healthcare x Digital 2021 will carry forth the goal of forging new partnerships and creating new solutions to solve Japan’s most critical community healthcare and individual patient challenges by focusing on three key areas tied to the digital transformation of society and which can help Japan continue to take care of—and provide even better care for—all its citizens.

ACCJ drives innovation by bringing together startups and big pharma

Last August, the American Chamber of Commerce in Japan (ACCJ) announced Healthcare x Digital, an XPRIZE-style competition meant to spur industry-changing technologies and connect Japan-based startups with major pharmaceutical companies and public officials.

Driven by the ACCJ Healthcare Committee—with support from the chamber’s Kansai Chapter—the initiative is led by ACCJ Corporate Sustaining Members AstraZeneca K.K., Bayer Yakuhin, Ltd., Deloitte Touche Tohmatsu LLC, and President’s Circle Member Eli Lilly Japan K.K.

The inaugural event was a huge success, with 28 companies submitting proposals. Three finalists were selected from this pool, and each emerged from the December 1 Pitch Event with awards and prize money to help them continue development of their ideas. Honors went to:

Bisu, Inc.: Best Innovation; the Moonshot Prize
MediFrame, Inc.: Best Value Proposition
MICIN, Inc.: Best Product

Great Opportunity

In a follow-up interview, Bisu Chief Executive Officer Daniel Maggs told The ACCJ Journal that participation in the Healthcare x Digital competition was important to them because “it matters for us to have validation and recognition from the medical industry, because we care very deeply about quality.”

Ryoichi Kusama, co-founder and senior vice president of MICIN, said that his company wants to help the medical industry change from within and become a player that can be trusted. Therefore, “the biggest plus is that it has expanded the collaboration with major pharmaceutical companies.”

And Mediframe CEO Atsushi Wada said that it meant a lot to him to be recognized by AstraZeneca, Bayer, and Lilly. “For them to see the potential in my company made me feel very pleased and encouraged.”

This year’s competition will once again bring together global healthcare leaders with top and emerging tech companies, entrepreneurs, and innovators in the search for new ideas.

Three Challenges

Overcoming the urban vs. rural healthcare divide
Reimagining the hospital of the future
Empowering patients to own their healthcare

These areas tie into the digital transformation of society and can help Japan continue to take care of—and provide even better care for—all its citizens. Demographic and economic trends are creating a strong contrast between rural and urban regions, and these shifts will require Japan to adopt new healthcare approaches and solutions. One question being asked in this year’s competition is how digital technology can break down the boundaries of distance to provide great and uniform care for everyone, no matter where they live.

Of course, reform of the healthcare system puts great pressure on hospitals to transform themselves and make better use of tools and resources. Technology is certainly key to that makeover, but what are the most innovative digital levers that can open up those paths to greater efficiency?

Another important part of ensuring that the healthcare system remains sustainable is empowering individuals to monitor their own health. A great example of such a tool is Bisu’s home health lab, for which the startup won ¥1 million in funding at last year’s competition. The elegant and easy-to-use system supports a range of tests that anyone can perform at home, allowing early disease detection and providing a way for individuals to track their health and adjust their daily lifestyle habits and decisions.

Joining Forces

At the core of Healthcare x Digital is the goal of bringing together emerging players—who have healthcare ideas, but require partners—with established players looking for innovative ideas to solve healthcare challenges.

This is made possible through the Healthcare x Digital ecosystem, which comprises four groups:

Innovators and startups
Established companies
Government organizations
Academic and non-profit institutions

These public, private, and non-profit sector players join forces to deliver all the pieces required to envision and execute groundbreaking solutions.

In the private sector, startups often have innovative digital healthcare ideas, but they lack the partnerships to evolve them. Teaming up with established companies that have the resources to develop an idea and bring it to market can allow the startup not only to grow as a company, but to change the course of future healthcare.

In the public and non-profit sectors, government bodies are searching for solutions to long-term healthcare challenges, such as cost, quality, and access. They want to drive innovation, which can lead to economic growth, but how to drive that change is not always clear. Academics and research institutions have insights that can help effect change, and they need a way to translate this into real-impact non-profit organizations.

Pitch Your Idea

Healthcare x Digital 2021 began accepting submissions on July 1 and the deadline is October 1. Evaluation of submissions is set to start on October 5. Pitches will be evaluated according to the following criteria:

Focus on patient and community needs
Healthcare x Digital value proposition
Need for an ecosystem to flourish

Everyone who participates in Healthcare x Digital will benefit from having their ideas reviewed by top executives from leading international healthcare and technology companies.

Those selected to participate in the Pitch Day will be invited to the full-day virtual event on October 14. Finalists will then take part in the HxD Ideas Day on November 11, a hybrid in-person and virtual event at which they will present to a panel of leading healthcare and pharmaceutical executives—all empowered to initiate business deals and new relationships on behalf of their global brands.

Monetary prizes will also be awarded, and the finalists will meet with senior executives from the organizing sponsors. Winning companies will receive mentoring and support from healthcare professionals and executives from organizing sponsors.

Join us to discover Japan’s most innovative healthcare ideas and develop partnerships to make them a reality.

Impact of Engagement

Japan faces a very modern problem: its success in delivering universal health coverage and fostering longer life expectancy has led to demographic and social changes that are giving rise to a new set of interconnected healthcare challenges. As the Japanese government moves to reform its healthcare system to address these challenges, new policy approaches will be necessary. With the right approach and policies, Japan can continue to improve the health of its citizens and create a blueprint that aging societies around the world can follow.

Continuing our efforts to communicate the value of investing in health

As the Japanese government moves to reform its healthcare system to address these challenges, new policy approaches will be necessary. Promoting innovation in all areas of the system will allow for increased healthy life expectancy and improved productivity, helping Japan move to the next phase of economic growth. And all this can be achieved while maintaining Japanese patients’ access to the most cutting-edge medicines, technologies, and treatments, while ensuring the security and stability of health and social care.

With the right approach and policies, Japan can continue to improve the health of its citizens and create a blueprint that aging societies around the world can follow.

More Agile Advocacy

On the back of our successful health and retirement work, the American Chamber of Commerce in Japan Healthcare Committee is now moving forward with our biennial health policy white paper. The upcoming report will look different compared with earlier reports. Previous white papers published by the Healthcare Committee have included topics ranging from the use of advance modeling and simulation in pandemic-related planning to improving cervical cancer screening. However, the wide range of topics made it difficult to maintain an up-to-date and compelling narrative in a single document.

Starting with our next white paper, we plan to create more succinct recommendations that fit with the overall messages of our committee viewpoints. The individual viewpoints will become the tools with which to dig deeper into issues featured in the white paper, thus creating a hybrid set of materials that can be updated regularly and used with greater agility in our advocacy. We are excited about the new format, and appreciate the ongoing contributions of member companies.

In the forthcoming white paper, we plan to explore a range of issues, focusing our recommendations across four key themes:

Investing in prevention, early detection, and treatment of disease
Maximizing healthcare quality and efficiency through digital and data innovation
Developing innovation policy, exploring reimbursement models
Ensuring the financial sustainability of Japan’s healthcare system

We believe that each theme will help Japan chart a path to more sustainable healthcare, and we encourage you to join upcoming Healthcare Committee meetings to learn more about our ongoing efforts and to help us finalize our recommendations.

To help you consider what form those final recommendations should take, here is more information about each of the key themes.

1. Prevention, early detection, treatment

In recent years, the Japanese government has shifted its focus from simply caring for disease to applying the practices of prevention, early detection, and earlier aggressive treatment to reduce overall healthcare expenditure and to sustain the productivity of its citizens. While significant progress has been made, much more could be done.

2. Digital and data innovation to boost quality, efficiency

Recognizing the need for better healthcare data management, the Japanese government has begun to centralize data platforms, accelerate data-driven innovation programs, and strengthen cybersecurity infrastructures to safeguard against external threats.

Yet, despite these efforts, Japan trails other developed countries in the implementation of a comprehensive healthcare data platform. Much more could be done to incentivize better collection and utilization of healthcare-related data.

3. Innovation policy, reimbursement models

In response to calls for the acceleration of healthcare innovation in Japan, the government launched a healthcare innovation initiative in 2014. Since then, the government has pursued several broad initiatives for research and development support, as well as the registration, authorization, commercialization, and evaluation of new healthcare technologies.

Despite this, reforms made to the pricing of, and reimbursement for, innovative medical technologies threaten to undo the progress made over recent years. With the clear purpose of delivering innovative healthcare to people in need, as soon and safely as possible, more could be done to allocate physical, human, and financial resources to maximize the potential for innovation.

4. The healthcare system’s financial sustainability

Japan’s healthcare system is respected around the world for its quality of care and contribution to long life expectancy. However, the aging society and low birthrate are straining a system designed, starting in 1868, primarily to control infectious and acute diseases in a different population structure. Improving the overall financial health of the system will be critical as more of the population ages and the workforce shrinks further.

ACCJ Healthcare White Papers & Viewpoints

The ACCJ Healthcare Committee strives to stimulate multi-stakeholder partnerships and discussions that will drive healthcare transformation by identifying practical, tangible actions and providing innovative solutions that address patient needs and ensure the sustainability of Japan’s healthcare system. Read advocacy documents and get involved in the committee’s ongoing efforts at: www.accj.or.jp/healthcare-advocacy.

Creative Cures

Twelve innovators share their solutions at the ACCJ’s Healthcare x Digital Pitch Day Event.